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Introduction
Since the US Congress designated the 1990s as the “Decade of the Brain,” much of the research
in psychiatry has endeavored to explain psychiatric disorders in terms of interconnected sets of
dysfunctional neural circuits. The shift in focus from behavioral manifestations to the underlying
neurobiology of mental illness has driven the field of biological psychiatry in general and the
Research Domain Criteria (RDoC) in particular. The aim of the RDoC is to identify brain
mechanisms that can explain the etiology and pathophysiology of psychiatric disorders, provide
earlier and more accurate diagnosis, and predict treatment responses and outcomes (Insel et al.,
2010; Casey et al., 2013). It incorporates genetics and behavioral science, including the influence
of the environment on neurodevelopment, into a broad neuroscientific paradigm of psychiatry.
By exploring the causes of mental illnesses and how these can inform interventions to modulate
neural pathways, the circuit-based RDoC offers a more satisfactory account of these illnesses
than the symptom-based Diagnostic and Statistical Manual of Mental Disorders (DSM-5). In its
current form, however, the RDoC may be too limited a theoretical model to provide a complete
understanding of why mental illness develops, how it progresses, and how different treatments
might control it. This raises the question of whether a more comprehensive version of the RDoC, or
a different paradigm altogether, will be needed to guide research and clinical practice in psychiatry.
History
Past attempts to conceptualize a sound paradigm for psychiatry proved elusive because of limited
knowledge of how brain function enables the mind and how brain dysfunction disables it.
Although many practitioners of psychoanalysis separate the psyche from the brain, the father of
psychoanalysis, Freud, attempted to formulate a scientific psychology of the mind in his Project
for a Scientific Psychology (Freud, 1895). This attempt was unsuccessful because at the time little
was known about the neurobiological underpinning of the psyche. The notorious first era of
psychosurgery developed and practiced by Moniz and Lima in the 1930s and 1940s and Freeman
and Watts in the 1940s and 1950s was based on the idea that psychiatric disorders were caused
by abnormalities in white-matter tracts in the prefrontal cortex and their projections to limbic
structures (Pressman, 1998). Creating lesions in these tracts and severing connections in neural
pathways to relieve symptoms was the ill-conceived rationale for Moniz and Lima’s prefrontal
leucotomy and Freeman and Watts’ frontal lobotomy. These procedures failed to achieve their
therapeutic goal and often resulted in significant cognitive, affective andmotor impairment inmany
patients. The advent of antidepressant and antipsychotic drugs in the 1950s obviated the need for
psychosurgery. This pharmacological approach to treating depression was based on a monoamine
hypothesis, which explained mood disorders in terms of abnormalities in mechanisms regulating
dopamine, adrenaline, noradrenaline and serotonin. Treating schizophrenia was based more
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specifically on a dopamine hypothesis, and later a glutamate
hypothesis, regarding abnormalities in these neurotransmitters.
While these hypotheses are consistent with the RDoC in offering
a neurobiological explanation of psychiatric disorders, they are
incomplete because they do not explain their etiology or predict
treatment outcomes. The RDoC’s inclusion of genetic and other
factors that influence neurotransmitters and neural circuits more
generally provides a more adequately informed model than
previous ones to account for mental illness.
Biomarkers, Neuromodulation, and
Neuroimaging
There are at least three respects in which the brain-systems
focus of the RDoC is a major advance in understanding and
treating psychiatric disorders: biomarkers; neuromodulation;
and neuroimaging that detects these signatures and guides these
techniques. Biomarkers may be mutations detected through
genetic testing and screening, abnormal proteins discovered
in bodily fluids, or structural and functional features of the
brain displayed in neuroimaging (Boksa, 2013). Detecting these
biological signatures might enable researchers and clinicians
to identify those at risk of developing a disorder when they
are in a pre-clinical state or have prodromal symptoms.
In schizophrenia, identifying a biomarker such as cerebral
white matter abnormalities when a person is experiencing
pre-psychotic positive symptoms such as mild hallucinations
and paranoia but before a first psychotic episode could
warrant early intervention (Lieberman et al., 2013). This
could minimize adverse changes in the brain and reduce the
chronic severity of the illness. In addition, biomarkers could
contribute to more accurate diagnosis and prognosis of this
and other conditions when symptoms alone are ambiguous.
Currently, the most promising area of biomarker research in
psychiatry is predicting responses to different treatments. In a
recent study involving patients with major depressive disorder
(MDD), hypometabolism in the insula displayed by functional
neuroimaging (PET) was associated with a positive response
to cognitive-behavioral therapy (CBT) in symptom reduction
but a poor response to the SSRI escitalopram (McGrath et al.,
2013). In contrast, insula hypermetabolism was associated with
a positive response to the drug and a poor response to CBT. This
study showed that a treatment-specific biomarker could guide
treatment selection for patients with MDD.
Another significant development in circuit-based psychiatry
has been the use of electrical current in deep brain stimulation
(DBS) and light in optogenetics to activate or inhibit neural
activity (Deisseroth et al., 2015). DBS is especially valuable
because it can both probe dysfunctional circuits in real-time and
modulate them in treatment-refractory depression and obsessive-
compulsive disorder (Lozano and Lipsman, 2013). MRI-guided
stereotactic functional neurosurgery for these disorders is
more effective and safer than the crude and often harmful
psychosurgery of the past. Biomarkers, neuromodulation and
neuroimaging together may lead to more personalized diagnosis
and treatment for psychiatric patients. They could contribute
to “precision medicine” for psychiatry, where “treatments are
targeted to the needs of individual patients on the basis of
genetic, biomarker, phenotypic, or psychosocial characteristics
that distinguish a given patient from other patients with similar
clinical presentations” (Jameson and Longo, 2015, p. 1).
Explaining psychiatric disorders in terms of dysfunctional
circuits in the brain also allows for alternative novel hypotheses
that go beyond monoamines and dopamine. Some of these are
based on findings of abnormalities in the brain’s resting-state
activity. Dehaene and Changeux (2011) have hypothesized that
schizophrenia is a disorder of consciousness caused by disrupted
information integration in the brain. Diffusion tensor imaging
of individuals with positive symptoms of schizophrenia supports
this hypothesis by revealing impaired connections between
prefrontal and posterior regions of the cortex, hippocampus
and thalamus, a distributed network that mediates conscious
processing (Kubicki et al., 2005). Similarly, Northoff (2014,
Ch. 27) has noted abnormalities in resting-state activity in
both schizophrenia and depression displayed by imaging. In
schizophrenia, there is impaired functional connectivity and low-
frequency fluctuations in midline regions. In depression, there
is hyperactivity in the midline network and hypoactivity in the
lateral network. This imbalance disrupts the connection between
the brain and the environment, with a pathological increase in
self-focus and a corresponding decrease in environment-focus at
the phenomenal level of consciousness.
Genetics might also help to explain some psychiatric disorders
as disorders of memory content. Generalized anxiety and
posttraumatic stress disorder (PTSD), for example, can be
described as conditions in which the representation of a
disturbing or traumatic memory of an event persists in the brain
to the point of becoming maladaptive or pathological (Schacter,
2001, Ch. 7). Why some people rather than others develop these
conditionsmay be partly explained by differences in transcription
factors such as cyclic AMP response element-binding protein
(CREB) and how these factors regulate the formation and storage
of episodic memories. In addition, differences in how genes
code for dopamine and regulate its release in the brain could
account for differences in placebo responses among patients
(Hall et al., 2015). This is another respect in which brain-
based mechanisms regulating cognitive and affective states can
contribute to precision medicine in diagnosing and treating
psychiatric disorders, where placebo responses are common.
By accounting for the variability of placebo responses among
patients with depression, anxiety and other conditions, these
mechanisms could improve therapy by inducing these responses
as additive to the salutary effects of pharmacological agents.
Limitations
The neural circuits on which the RDoC focuses may not
adequately consider the effects of neuro-immune and neuro-
endocrine interactions in the pathophysiology of depression,
schizophrenia and possibly other disorders. Cytokines released
in response to infection may result in elevated levels of
inflammatory biomarkers in the blood. These in turn may lead
to inflammatory changes in the brain and alteration of neural
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circuits that could trigger or exacerbate mood disturbances and
cognitive and volitional impairment in depression (Raison et al.,
2006, 2013). As another example of neuro-immune interaction,
the neuropathology in some psychiatric disorders may be traced
to prenatal events. Maternal antibodies produced in response
to infection during pregnancy can activate immune processes
that can trigger an inflammatory reaction in the fetal brain and
alter its development (Patterson, 2011). There is some association
between this type of reaction and the risk of schizophrenia and
autism in offspring. These and other adverse processes in the
maternal-fetal environment may be part of an explanation for
abnormalities in synaptic pruning, which has been suggested as
one response to the question of why many neurodevelopmental
disorders emerge during adolescence (Paus et al., 2008). The
extent to which maternal antibodies are present during fetal
gestation and cause an inflammatory reaction in the fetus
might also partly account for behavioral and other phenotypic
differences among individuals affected by schizophrenia. Neuro-
immune interactions during the prenatal period underscore the
importance of prenatal care and how more biologically informed
reproductive choices might prevent some forms of mental illness.
Another limitation of circuit-level explanations is that they
cannot account for how psychosocial factors influence people’s
stress responses to environmental stimuli or the variability of
these responses. Chronic stress can induce hyperactivity in the
amygdala fear system and impair the reward system in causing
depressive symptoms. While biological psychiatry can explain
this process in neurobiological terms, it cannot explain the
causal role of an affected person’s mental states in the etiology
of depression. Nor can circuit-level explanations of this and
other psychiatric disorders account for the phenomenology
of experiencing delusions, hallucinations, avolition, anhedonia,
and low or elevated mood. Yet the subjective aspect of these
disorders is essential to knowing how people are affected by
them and validating symptom relief from different treatments
because they are diseases of dysfunctional brain-mind and mind-
brain interaction. Although the identification of more psychiatric
biomarkers through genetic testing and neuroimaging will
contribute to a better understanding of psychiatric disorders,
it will not offer a complete explanation of why people develop
these disorders or why some respond more favorably to
treatment than others. Because of the multifactorial etiology
of depression and other conditions and the heterogeneity of
expression of their symptoms, examining them in terms of
neural circuits will not replace but supplement and refine
other criteria for predicting, diagnosing, and monitoring
responses to interventions to control and possibly prevent
them.
Conclusion
Psychiatric disorders result from interaction among neurons,
genes, immune and endocrine systems and the affected person’s
psychological response to the natural and social environment.
Explaining these disorders at a brain-systems level is necessary
but not sufficient to understand how they develop and how they
can be treated with pharmacological and behavioral therapies
targeted to individuals affected by them. Ordered and disordered
states of brain and mind are influenced by factors both inside
and outside of the brain. Mental illness currently constitutes 7.4%
of the global burden of disease, and its incidence will increase
exponentially in the future (Becker and Kleinman, 2013). The
World Health Organization (2012) estimates that depression will
be the leading cause of global disease burden by 2030. Despite
its limitations, RDoC offers the most conceptually coherent
and scientifically sound paradigm for explaining psychiatric
disorders. Still, a more comprehensive version of the RDoC that
includes processes in addition to circuit-level mechanisms will
put psychiatry in a better position tomeet the challenges posed by
mental illness. This is not a novel model but a further stage of an
evolving non-reductive understanding of mental illness based on
complex interactions among neurobiological, psychological and
social factors. Such a model will enable researchers and clinicians
to more effectively relieve the burden of psychiatric disorders and
improve the quality of life for the millions of patients suffering
from these diseases of the brain and mind.
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